Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin 5‑HT1B/1D receptor agonist (triptan) presented as a nasal spray for nasal administration. It provides rapid relief of acute migraine attacks in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards and ensure product integrity throughout the supply chain. The product is manufactured under GMP conditions and is approved for use across European Union member states.

Imigran (sumatriptan) is indicated for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine without aura: reduces headache intensity and associated symptoms. - Migraine with aura: alleviates pain and visual disturbances. - Acute migraine attacks: shortens the duration of the episode and improves functional ability.

Common Side Effects: - Nasal discomfort or irritation - Altered taste sensation - Dizziness or light‑headedness - Nausea or mild stomach upset

Serious or Rare Side Effects: - Chest pain or tightness indicating possible coronary vasospasm - Severe allergic reaction such as anaphylaxis - Signs of serotonin syndrome, including agitation, hyperthermia, and muscle rigidity

Before using Imigran, consider the following precautions: - Assess cardiovascular risk: avoid in patients with known coronary artery disease. - Avoid concomitant use with MAO inhibitors or ergot alkaloids. - Caution in uncontrolled hypertension: monitor blood pressure closely. - Use carefully in hepatic impairment: dose adjustment may be required. - Discontinue if hypersensitivity to sumatriptan or any formulation component is observed. - Store at room temperature: keep in the original container, protect from moisture and light.

Imigran may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Ergot derivatives: additive vasoconstrictive effects. - Other triptans: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible reduction in blood‑pressure‑lowering effect. - SSRIs or SNRIs: monitor for signs of serotonin excess.